<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369210</url>
  </required_header>
  <id_info>
    <org_study_id>139/17F</org_study_id>
    <nct_id>NCT03369210</nct_id>
  </id_info>
  <brief_title>Liberal Transfusion Strategy in Elderly Patients</brief_title>
  <acronym>LIBERAL</acronym>
  <official_title>Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Patrick Meybohm, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, multicentre, open, randomised, controlled clinical trial elderly
      patients (≥ 70 years) undergoing intermediate- or high-risk non-cardiac surgery will be
      randomised either to a liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl
      (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5
      mmol/l)) or restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5
      g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl
      (4.7-5.6 mmol/l). Primary efficacy endpoint: is a composite of death from any cause and
      anaemia-associated, ischaemic events (defined as acute myocardial infarction, acute ischaemic
      stroke, acute kidney injury stage III, acute mesenteric ischaemia, acute peripheral vascular
      ischaemia) within 90 days after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of a composite endpoint</measure>
    <time_frame>90 days</time_frame>
    <description>Composite of death and anaemia-associated events I. All-cause mortality defined as death from any cause. II. Acute myocardial infarction confirmed by a cardiologist III. Acute ischaemic stroke confirmed by a neurologist IV. Acute kidney injury (stage III) defined according to the Kidney Disease Improving Global Outcomes criteria: Increase of plasma creatinine level ≥ 3 times within a time window of 7 days or initiation of renal replacement therapy.
V. Acute mesenteric ischaemia defined as ischaemia confirmed by intervention (abdominal surgery or mesenteric angiography).
VI. Acute peripheral vascular ischaemia defined as a new non-thrombotic compromised circulation in a limb confirmed by angiography and/or leading to surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving red blood cell transfusion</measure>
    <time_frame>hospital discharge (an anticipated average of 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of red blood cell units transfused</measure>
    <time_frame>hospital discharge (an anticipated average of 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay in the intensive care unit</measure>
    <time_frame>hospital discharge (an anticipated average of 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay in hospital</measure>
    <time_frame>hospital discharge (an anticipated average of 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with acute kidney injury stage I-II</measure>
    <time_frame>hospital discharge (an anticipated average of 10 days)</time_frame>
    <description>The occurrence of acute kidney injury (stage I or II) defined according to the Kidney Disease Improving Global Outcomes criteria (stage I: increase of plasma creatinine level ≥ 1.5-1.9 times baseline or ≥ 0.3mg/dl within 48 hours; stage II: increase of plasma creatinine level ≥ 2-2.9 times baseline within a time window of 7 days) during the initial hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to infection</measure>
    <time_frame>90 days</time_frame>
    <description>Time to (first) infection (infection requiring therapeutic intravenous antibiotic treatment (pneumonia, wound infection, sepsis, central line associated blood stream infection)) during the initial hospital stay or leading to hospital re-admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-hospitalisation</measure>
    <time_frame>90 days</time_frame>
    <description>Time to (first) re-hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional status (Barthel index)</measure>
    <time_frame>90 days</time_frame>
    <description>Functional status (assessed by Barthel Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>90 days</time_frame>
    <description>Health-related quality of life (assessed by EuroQoL EQ-5D and 12-item World Health Organisation Disability Assessment Schedule WHODAS 2.043) by telephone questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any individual component of the composite</measure>
    <time_frame>1 year</time_frame>
    <description>composite components (all-cause mortality, acute myocardial infarction, acute stroke, acute kidney injury stage III, acute mesenteric ischaemia, and/or acute peripheral vascular ischaemia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2470</enrollment>
  <condition>Transfusion-dependent Anemia</condition>
  <condition>Surgery</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Liberal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>red blood cell transfusion trigger</intervention_name>
    <description>patients receive a RBC unit with different target ranges for the post-transfusion Hb levels</description>
    <arm_group_label>Liberal</arm_group_label>
    <arm_group_label>Restrictive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 70 years of age scheduled for intermediate- or high-risk non-cardiac
             surgery will be registered

          -  Registered patients will be randomised only if they indeed develop severe anaemia (if
             Hb level falls ≤ 9 g/dl) during surgery (=day 0) or day 1, 2, or 3 after surgery

        Exclusion Criteria:

          -  preoperative Hb level ≤ 9 g/dl

          -  chronic kidney disease requiring dialysis

          -  suspected lack of compliance with follow-up procedures

          -  participation in other interventional trials

          -  expected death within 3 months

          -  inability to provide informed consent with absence of a legally authorised
             representative/ legal guardian

          -  temporary inability to provide informed consent

          -  previous participation in our trial

          -  patients who are prevented from having blood and blood products according to a system
             of beliefs (e.g. Jehovah's Witnesses)

          -  preoperative autologous blood donation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Meybohm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Meybohm, MD</last_name>
    <phone>+4969630186668</phone>
    <email>patrick.meybohm@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Stoppe</last_name>
    </contact>
    <investigator>
      <last_name>Ana Kowak</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Coburn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha Treskatsch</last_name>
    </contact>
    <investigator>
      <last_name>Roland Francis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kienbaum</last_name>
    </contact>
    <investigator>
      <last_name>Tanja Meyer-Treschan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <email>patrick.meybohm@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Kai Zacharowski, MD, PhD, FRCA</last_name>
    </contact_backup>
    <investigator>
      <last_name>Patrick Meybohm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Zacharowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erhard Seifried, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Lindau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus M Mueller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Geisen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität Giessen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sander</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sixten Selleng</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Greinacher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Heringlake</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zarbock</last_name>
    </contact>
    <investigator>
      <last_name>Melanie Meersch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kranke</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.liberal-trial.de</url>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Patrick Meybohm, M.D.</investigator_full_name>
    <investigator_title>Prof. Dr. Patrick Meybohm</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

